Statements (112)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Breztri_Aerosphere
|
| gptkbp:activities |
dual bronchodilator
Bronchodilation |
| gptkbp:availability |
No generic available
|
| gptkbp:clinical_trial |
gptkb:asthma
Improved quality of life COPD Phase III ongoing studies positive efficacy reduced exacerbations improved lung function Well tolerated Breztri vs. other COPD medications Breztri vs. placebo Improved lung function Long-term management of COPD Reduced exacerbations |
| gptkbp:contraindication |
hypersensitivity to components
Hypersensitivity to components |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:dosage_form |
Aerosol
metered-dose inhaler 160/4.5 mcg 80/4.5 mcg |
| gptkbp:effective_date |
2019-09-30
FDA approved 2020-03-30 |
| gptkbp:formulation |
inhalation aerosol
Inhalation aerosol |
| gptkbp:frequency |
twice daily
|
| gptkbp:healthcare |
provided by Abb Vie
|
| https://www.w3.org/2000/01/rdf-schema#label |
Breztri
|
| gptkbp:indication |
Maintenance treatment of COPD
|
| gptkbp:ingredients |
gptkb:Breztri_Aerosphere
breztri |
| gptkbp:interacts_with |
corticosteroids
diuretics beta-blockers |
| gptkbp:invention |
gptkb:Abb_Vie
Patent protected |
| gptkbp:is_atype_of |
R03 A K06
|
| gptkbp:is_monitored_by |
lung function tests
symptom control |
| gptkbp:is_used_for |
gptkb:Chronic_obstructive_pulmonary_disease_(COPD)
chronic obstructive pulmonary disease |
| gptkbp:label |
FDA approved labeling
|
| gptkbp:launch_date |
2019-09-30
|
| gptkbp:manager |
Inhalation
inhalation |
| gptkbp:manufacturer |
gptkb:temple
gptkb:Abb_Vie_Inc. |
| gptkbp:market |
gptkb:2020
|
| gptkbp:marketed_as |
gptkb:Breztri_Aerosphere
gptkb:legislation gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:packaging |
pressurized metered-dose inhaler
Pressurized metered-dose inhaler |
| gptkbp:pharmacokinetics |
gptkb:battle
bronchodilation rapid absorption Absorption through the lungs Long-acting beta-agonist and corticosteroid |
| gptkbp:population |
Adults
adults and children over 12 provided with medication |
| gptkbp:price |
Variable by insurance
|
| gptkbp:provides_information_on |
gptkb:GOLD_guidelines
FDA guidelines NICE guidelines recommended for COPD management recommended for asthma management |
| gptkbp:requires |
gptkb:battle
|
| gptkbp:research_focus |
COPD management
Combination therapy effectiveness Efficacy in diverse populations Long-term safety |
| gptkbp:safety_features |
generally well tolerated
Monitor for adrenal insufficiency Not for acute bronchospasm Potential for cardiovascular effects Risk of hypersensitivity reactions Risk of pneumonia |
| gptkbp:scholarships |
available through Abb Vie
|
| gptkbp:shelf_life |
24 months
|
| gptkbp:side_effect |
gptkb:healthcare_organization
gptkb:Cough gptkb:Nausea gptkb:Pneumonia Headache dizziness headache nausea cough Dysphonia throat irritation Cardiovascular events Hypokalemia Throat irritation oral thrush cardiovascular effects Upper respiratory tract infection Oral thrush |
| gptkbp:social_structure |
C23 H31 N3 O5 S
|
| gptkbp:storage |
Store at room temperature
store at room temperature |
| gptkbp:supports |
EU and US
|
| gptkbp:type_of_care |
important for efficacy
Improved with proper education |